Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractional, heterologous primary COVID-19 vaccination with BNT162b2 booster in 5–11-year-old Thai children
TCTR20220406002Phase 2Completed
- Sponsor
- Program Management Unit for Competitiveness
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Program Management Unit for Competitiveness. Started Apr 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220406002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220406002.